Sky Labs Pitches Ring-Based Monitor as Alternative to Traditional ABPM

The summit, which drew representatives from major pharmaceutical players like Roche and Novartis, focused on integrating wearable technology into clinical trial workflows. Sky Labs argued that conventional cuff-type monitors frequently cause sleep disturbances, leading to high dropout rates and incomplete data sets. Citing research that indicates over 70% of participants experience sleep disruption with standard cuffs, the company positioned its ring-type monitor as a more tolerable alternative for long-term blood pressure tracking.

Beyond clinical trials, the device is designed to capture Real-World Evidence (RWE) regarding how patients respond to existing medications over time. By tracking fluctuations alongside dosage and lifestyle patterns, the platform provides a continuous stream of vital signs that traditional methods struggle to maintain. Sky Labs CEO Jack Byunghwan Lee emphasized that the device has already gained traction in its home market, where it is currently covered under South Korea’s national health insurance and included in the Korean Guidelines for the Management of Hypertension.

Sky Labs is now targeting global pharmaceutical partnerships to scale the use of its data platform. With the device already in use for a large-scale cohort study managed by the Korea Disease Control and Prevention Agency, the company is looking to translate its domestic clinical validation into broader adoption within international drug development projects.